LORETTA NASTOUPIL to Antibodies, Monoclonal
This is a "connection" page, showing publications LORETTA NASTOUPIL has written about Antibodies, Monoclonal.
Connection Strength
0.446
-
The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Rev Anticancer Ther. 2013 Sep; 13(9):1089-108.
Score: 0.186
-
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820.
Score: 0.072
-
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109.
Score: 0.068
-
Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. Curr Oncol Rep. 2015 Jul; 17(7):30.
Score: 0.053
-
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs. 2021 Jul; 35(4):459-468.
Score: 0.020
-
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67.
Score: 0.019
-
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 06 10; 36(17):1714-1768.
Score: 0.016
-
A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2012 Dec; 12(6):393-9.
Score: 0.011